Mar 23, 2021
Precigen Announces First Patient Dosed for PRGN-2012 AdenoVerse™ Immunotherapy in Patients with Recurrent Respiratory Papillomatosis (RRP)
Mar 18, 2021
Precigen Receives FDA Orphan Drug Designation for PRGN-2012 AdenoVerse™ Immunotherapy in Patients with Recurrent Respiratory Papillomatosis (RRP)
Jan 26, 2021
Precigen Announces Closing of Public Offering of Common Stock and Full Exercise of Option to Purchase Additional Shares
Displaying 1 - 10 of 13
May 21, 2021 at 12:45 PM EDT
Oral presentation of the abstract "Adenovirus vectors for human therapeutics." The abstract will be presented by Douglas E. Brough, PhD, Head of Research, Precigen. Presented in Session 12: Gene Delivery.
Jun 04, 2021 at 9:00 AM EDT
Trial-in-progress poster presentation of the PRGN-2009 abstract "First-in-human Phase I/II trial of PRGN-2009 vaccine as monotherapy or with bintrafusp alfa in patients with recurrent/metastatic (R/M) human papillomavirus (HPV)-associated cancers (HPVC) and as neoadjuvant/induction therapy in locoregionally advanced (LA) HPV oropharyngeal (OP) and sinonasal (SN) squamous cell cancer (SCC)." The poster presentation will be presented by Charalampos S. Floudas, MD, DMSc, MS, Assistant Research Physician, Genitourinary Malignancies Branch at the Center for Cancer Research at the National Cancer Institute (NCI). Presented in Poster Sessions: Head and Neck Cancer.
Jun 10, 2021 at 5:05 PM - 5:20 PM EDT
Oral presentation of the AG019 abstract "Lactococcus lactis producing Proinsulin and IL-10 therapy increases Antigen Specific Regulatory T-cells in Monotherapy and in Combination with an anti-CD3 Monoclonal Antibody (Teplizumab) in newly diagnosed T1D patients." The abstract will be presented by Kevan Herold, MD, CNH Long Professor of Immunobiology and of Medicine (Endocrinology) at the Yale School of Medicine. Presented in Thematic Sessions: Human Microbiome.